ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in discovering, developing and commercializing novel, differentiated therapies to address unmet medical needs in cancer, Read More ›

ROCKVILLE, Md. and SUZHOU, China, Feb. 23, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management is Read More ›

ROCKVILLE, Md. and SUZHOU, China, Feb. 09, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company, a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management Read More ›

ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation Bruton’s tyrosine kinase (BTK)-targeted protein degrader, Read More ›

Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presence Next-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipeline Multiple global registrational Phase III trials are progressing rapidly ROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Read More ›

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company’s global innovative pipeline. Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies. ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) Read More ›

ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management Read More ›

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival) ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International Read More ›

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy  Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy data support potential advancement to earlier treatment lines for a broader patient population ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE Read More ›

By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectively High-risk IKZF1plus patients showed 90% molecular response rate Low-intensity chemotherapy combination achieved deep responses with favorable safety profile ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) Read More ›